• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将原发性根治性切除的预后因素外推至可通过射频消融治疗的切除后复发性肝细胞癌

Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation.

作者信息

Ma Hui, Li Zhongchen, Yuan Jia, Zhang Lan, Xie Xiaoying, Yin Xin, Chen Rongxin, Ren Zhenggang

机构信息

Liver Cancer Institute, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

出版信息

Gastroenterol Res Pract. 2021 Jan 2;2021:8878417. doi: 10.1155/2021/8878417. eCollection 2021.

DOI:10.1155/2021/8878417
PMID:33488700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7801068/
Abstract

OBJECTIVE

Recurrence after curative resection for hepatocellular carcinoma (HCC) is a major cause of death from this disease. Factors of primary curative resection are available and potential in the prognosis of follow-up treatment. Our aim was to assess the prognostic significance of primary curative resection factors in recurrent HCC patients undergoing radiofrequency ablation therapy (RFA).

METHODS

In this retrospective study, we assessed 235 patients who underwent limited RFA of HCC recurrences (tumors ≤ 5 cm; nodules ≤ 3) after primary curative resection. Factors of primary curative resection were collected, and overall survival and recurrence-free survival were evaluated by the Kaplan-Meier method. Univariate and multivariate analyses were used to identify significant prognostic factors.

RESULTS

After a median follow-up of 36 months, 54 patients died, and 128 patients had hepatic recurrence. On univariate analyses, patients whose primary tumors were less differentiated ( = 0.032 and = 0.048) and required less time to recur ( = 0.013 and = 0.001) after curative resection displayed poorer overall survival and higher recurrence rates following RFA. On multivariate analyses, the pathologic tumor grade ( = 0.026 and = 0.038) and recurrence-free survival after primary curative resection ( = 0.028 and < 0.001) emerged as independent risk factors of survival and HCC recurrence.

CONCLUSIONS

Primary tumor differentiation and time to recurrence after curative resection are viable prognostic factors of overall survival and further recurrence risk in patients undergoing RFA of recurrent HCC.

摘要

目的

肝细胞癌(HCC)根治性切除术后复发是导致该病死亡的主要原因。原发性根治性切除的因素对于后续治疗的预后具有参考价值和潜在意义。我们的目的是评估原发性根治性切除因素对接受射频消融治疗(RFA)的复发性HCC患者的预后意义。

方法

在这项回顾性研究中,我们评估了235例在原发性根治性切除术后接受局限性RFA治疗HCC复发(肿瘤≤5 cm;结节≤3个)的患者。收集原发性根治性切除的因素,并采用Kaplan-Meier法评估总生存期和无复发生存期。采用单因素和多因素分析来确定显著的预后因素。

结果

中位随访36个月后,54例患者死亡,128例患者出现肝复发。单因素分析显示,原发性肿瘤分化程度较低(P = 0.032和P = 0.048)且根治性切除后复发所需时间较短(P = 0.013和P = 0.001)的患者,RFA治疗后的总生存期较差,复发率较高。多因素分析显示,病理肿瘤分级(P = 0.026和P = 0.038)以及原发性根治性切除后的无复发生存期(P = 0.028和P < 0.001)是生存和HCC复发的独立危险因素。

结论

原发性肿瘤分化程度和根治性切除后复发时间是接受复发性HCC RFA治疗患者总生存期和进一步复发风险的可行预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70cc/7801068/b9cf3294b0e9/GRP2021-8878417.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70cc/7801068/b9cf3294b0e9/GRP2021-8878417.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70cc/7801068/b9cf3294b0e9/GRP2021-8878417.001.jpg

相似文献

1
Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation.将原发性根治性切除的预后因素外推至可通过射频消融治疗的切除后复发性肝细胞癌
Gastroenterol Res Pract. 2021 Jan 2;2021:8878417. doi: 10.1155/2021/8878417. eCollection 2021.
2
Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.射频消融与再次切除治疗初始根治性切除后复发的≤5cm 肝细胞癌。
Eur Radiol. 2020 Nov;30(11):6357-6368. doi: 10.1007/s00330-020-06990-8. Epub 2020 Jun 11.
3
A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.根治性切除术后肝细胞癌肝内复发的预测模型和治疗策略。
World J Surg. 2011 Jan;35(1):170-7. doi: 10.1007/s00268-010-0794-8.
4
Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.经动脉化疗栓塞与手术/射频消融治疗伴或不伴微血管侵犯的复发性肝细胞癌。
J Gastroenterol Hepatol. 2014 May;29(5):1056-64. doi: 10.1111/jgh.12507.
5
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.肝细胞癌肝切除术后复发:危险因素、治疗及预后
Surgery. 2007 Mar;141(3):330-9. doi: 10.1016/j.surg.2006.06.028. Epub 2006 Nov 1.
6
Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection.复发性肝细胞癌:一种强调首次切除病理特征影响的西方策略。
Surgery. 2015 Mar;157(3):454-62. doi: 10.1016/j.surg.2014.10.011. Epub 2014 Nov 6.
7
Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent.肝移植对于因射频消融或有治愈意图的肝切除术后复发的肝细胞癌患者来说是一种有效的挽救性治疗方法。
Ann Surg Oncol. 2018 Apr;25(4):991-999. doi: 10.1245/s10434-017-6329-x. Epub 2018 Jan 11.
8
Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.钆塞酸增强磁共振上无强化的肝胆期低信号结节有助于确定 HCC 的治疗方法。
Eur Radiol. 2019 Jun;29(6):3122-3131. doi: 10.1007/s00330-018-5941-x. Epub 2019 Jan 14.
9
Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases.根治性治疗后首次复发肝细胞癌的射频消融疗效:与原发性病例的比较。
Eur J Radiol. 2015 Aug;84(8):1540-1545. doi: 10.1016/j.ejrad.2015.04.020. Epub 2015 Apr 28.
10
Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival.早期肝细胞癌的经皮射频消融:生存的危险因素
World J Gastroenterol. 2014 Feb 14;20(6):1585-93. doi: 10.3748/wjg.v20.i6.1585.

本文引用的文献

1
New advances in the diagnosis and management of hepatocellular carcinoma.肝细胞癌的诊断与治疗新进展。
BMJ. 2020 Oct 26;371:m3544. doi: 10.1136/bmj.m3544.
2
Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.射频消融与再次切除治疗初始根治性切除后复发的≤5cm 肝细胞癌。
Eur Radiol. 2020 Nov;30(11):6357-6368. doi: 10.1007/s00330-020-06990-8. Epub 2020 Jun 11.
3
Optimizing curative management of hepatocellular carcinoma.优化肝细胞癌的治疗管理
Liver Int. 2020 Feb;40 Suppl 1:109-115. doi: 10.1111/liv.14345.
4
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌:趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
5
Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma.肿瘤分期中小血管侵犯对肝细胞癌的预后意义。
World J Surg Oncol. 2017 Dec 19;15(1):225. doi: 10.1186/s12957-017-1292-3.
6
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.2015 年全球疾病负担研究:1990 年至 2015 年全球、区域和国家一级原发性肝癌及相关病因负担。
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. doi: 10.1001/jamaoncol.2017.3055.
7
Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection.米兰标准内肝细胞癌根治性切除术后早期复发的预测
Oncotarget. 2017 Jun 28;8(38):63299-63310. doi: 10.18632/oncotarget.18799. eCollection 2017 Sep 8.
8
Patients with early recurrence of hepatocellular carcinoma have poor prognosis.肝细胞癌早期复发的患者预后较差。
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):279-288. doi: 10.1016/s1499-3872(16)60181-9.
9
Treatment and outcomes of recurrent hepatocellular carcinomas.复发性肝细胞癌的治疗与转归
Langenbecks Arch Surg. 2017 Aug;402(5):737-744. doi: 10.1007/s00423-017-1582-9. Epub 2017 May 11.
10
Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma.肝细胞癌根治性肝切除术后的早期复发危险因素及模式
Surg Oncol. 2016 Mar;25(1):24-9. doi: 10.1016/j.suronc.2015.12.002. Epub 2015 Dec 12.